The recall was prompted after a potentially carcinogenic impurity, N-Nitroso-N-methyl-4-aminobutyric acid, was detected in the medication, which is used to treat high blood pressure.
The drugmaker hasn’t received any reports of adverse events related to the recalled products.
Macleods is the latest drugmaker to recall its generic heart drugs over the detection of a potential carcinogen.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.